Platelet Lysate as Replacement for Fetal Bovine Serum in Mesenchymal Stromal Cell Cultures

Mesenchymal stromal cells (MSC) emerged as highly attractive in cell-based regenerative medicine. Initially thought to provide cells capable of differentiation towards mesenchymal cell types (osteoblasts, chondrocytes, adipocytes etc.), by and by potent immunoregulatory and pro-regenerative activities have been discovered, broadening the field of potential applications from bone and cartilage regeneration to wound healing and treatment of autoimmune diseases. Due to the limited frequency in most tissue sources, ex vivo expansion of MSC is required compliant with good manufacturing practice (GMP) guidelines to yield clinically relevant cell doses. Though, still most manufacturing protocols use fetal bovine serum (FBS) as cell culture supplement to isolate and to expand MSC. However, the high lot-to-lot variability as well as risk of contamination and immunization call for xenogenic-free culture conditions. In terms of standardization, chemically defined media appear as the ultimate achievement. Since these media need to maintain all key cellular and therapy-relevant features of MSC, the development of chemically defined media is still - albeit highly investigated - only in its beginning. The current alternatives to FBS rely on human blood-derived components: plasma, serum, umbilical cord blood serum, and platelet derivatives like platelet lysate. Focusing on quality aspects, the latter will be addressed within this review.

[1]  Ludwika Kreja,et al.  GMP-Compliant Isolation and Expansion of Bone Marrow-Derived MSCs in the Closed, Automated Device Quantum Cell Expansion System , 2013, Cell transplantation.

[2]  N. Brick Autologous platelet-rich plasma for treating chronic wounds. , 2013, The American journal of nursing.

[3]  O. Lindvall,et al.  Regulation of stem cell therapies under attack in Europe: for whom the bell tolls , 2013, The EMBO journal.

[4]  R. Henschler,et al.  Cultivation in human serum reduces adipose tissue-derived mesenchymal stromal cell adhesion to laminin and endothelium and reduces capillary entrapment. , 2013, Stem cells and development.

[5]  H. Hoeksema,et al.  The use of platelet-rich plasma in plastic surgery: a systematic review. , 2013, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[6]  Gregor Bein,et al.  Good manufacturing practice-compliant animal-free expansion of human bone marrow derived mesenchymal stroma cells in a closed hollow-fiber-based bioreactor. , 2013, Biochemical and biophysical research communications.

[7]  C. Choong,et al.  MSCs into adipogenic, chondrogenic, and osteogenic lineages identify markers and signaling pathways important in differentiation of growth of mesenchymal stem cells (MSCs): transcriptional profiling can , and FGF signaling is important for differentiation and β PDGF, TGF- , 2013 .

[8]  Karen Bieback,et al.  Expansion of Mesenchymal Stem/Stromal cells under xenogenic-free culture conditions. , 2013, Advances in biochemical engineering/biotechnology.

[9]  C. Lange,et al.  Platelet lysate suppresses the expression of lipocalin-type prostaglandin D2 synthase that positively controls adipogenic differentiation of human mesenchymal stromal cells. , 2012, Experimental cell research.

[10]  Rachel M. Buchanan,et al.  Adult and umbilical cord blood-derived platelet-rich plasma for mesenchymal stem cell proliferation, chemotaxis, and cryo-preservation. , 2012, Biomaterials.

[11]  M. Zenke,et al.  Donor Age of Human Platelet Lysate Affects Proliferation and Differentiation of Mesenchymal Stem Cells , 2012, PloS one.

[12]  A. Ignatius,et al.  Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components , 2012, Cytotherapy.

[13]  N. Simunovic,et al.  Efficacy of autologous platelet-rich plasma use for orthopaedic indications: a meta-analysis. , 2012, The Journal of bone and joint surgery. American volume.

[14]  F. Locatelli,et al.  Mesenchymal stromal cell therapy: a revolution in Regenerative Medicine? , 2012, Bone Marrow Transplantation.

[15]  L. Moretta,et al.  Mesenchymal stem cells expanded in human platelet lysate display a decreased inhibitory capacity on T‐ and NK‐cell proliferation and function , 2011, European journal of immunology.

[16]  M. Murray,et al.  The effect of platelet concentrates on graft maturation and graft-bone interface healing in anterior cruciate ligament reconstruction in human patients: a systematic review of controlled trials. , 2011, Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association.

[17]  D. Strunk,et al.  Immunomodulative Efficacy of Bone Marrow-Derived Mesenchymal Stem Cells Cultured in Human Platelet Lysate , 2011, Journal of Clinical Immunology.

[18]  Arnold I Caplan,et al.  The MSC: an injury drugstore. , 2011, Cell stem cell.

[19]  A. Dietz,et al.  Platelet Lysate Consisting of a Natural Repair Proteome Supports Human Mesenchymal Stem Cell Proliferation and Chromosomal Stability , 2011, Cell transplantation.

[20]  S. Giannini,et al.  Mesenchymal stem cells and platelet lysate in fibrin or collagen scaffold promote non‐cemented hip prosthesis integration , 2011, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[21]  A. Nurden Platelets, inflammation and tissue regeneration , 2011, Thrombosis and Haemostasis.

[22]  K. Cherian,et al.  “Humanized” Stem Cell Culture Techniques: The Animal Serum Controversy , 2011, Stem cells international.

[23]  Thierry Burnouf,et al.  Expansion of adipose tissue mesenchymal stromal progenitors in serum‐free medium supplemented with virally inactivated allogeneic human platelet lysate , 2011, Transfusion.

[24]  A. Cometa,et al.  Ex vivo expansion of mesenchymal stromal cells. , 2011, Best practice & research. Clinical haematology.

[25]  P. Bugert,et al.  Pathogen Reduction in Blood Products: What’s Behind These Techniques? , 2011, Transfusion Medicine and Hemotherapy.

[26]  Karen Bieback,et al.  Translating Research into Clinical Scale Manufacturing of Mesenchymal Stromal Cells , 2011, Stem cells international.

[27]  M. Pevsner-Fischer,et al.  The Origins of Mesenchymal Stromal Cell Heterogeneity , 2011, Stem Cell Reviews and Reports.

[28]  M. Andreeff,et al.  Concise Review: Dissecting a Discrepancy in the Literature: Do Mesenchymal Stem Cells Support or Suppress Tumor Growth? , 2010, Stem cells.

[29]  Walter Pfaller,et al.  Alternatives to the use of fetal bovine serum: human platelet lysates as a serum substitute in cell culture media. , 2011, ALTEX.

[30]  C. Centeno,et al.  Safety and complications reporting update on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. , 2011, Current stem cell research & therapy.

[31]  A. Barbero,et al.  Fibroblast growth factor 2 and platelet-derived growth factor, but not platelet lysate, induce proliferation-dependent, functional class II major histocompatibility complex antigen in human mesenchymal stem cells. , 2010, Arthritis and rheumatism.

[32]  D. Cyranoski Korean deaths spark inquiry , 2010, Nature.

[33]  A. Tuffs Stem cell treatment in Germany is under scrutiny after child’s death , 2010, BMJ : British Medical Journal.

[34]  G. Lucchini,et al.  Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[35]  Donald G Phinney,et al.  Defining the risks of mesenchymal stromal cell therapy. , 2010, Cytotherapy.

[36]  P. Bugert,et al.  Altered gene expression in human adipose stem cells cultured with fetal bovine serum compared to human supplements. , 2010, Tissue engineering. Part A.

[37]  E. Seifried,et al.  Buffy‐coat‐derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred? , 2010, Vox sanguinis.

[38]  A. Villa,et al.  Characterization of platelet lysate cultured mesenchymal stromal cells and their potential use in tissue-engineered osteogenic devices for the treatment of bone defects. , 2010, Tissue engineering. Part C, Methods.

[39]  O. Korsgren,et al.  Photochemical pathogen inactivation of human serum enables its large‐scale application in clinical cell transplantation , 2010, Vox sanguinis.

[40]  J. Kramer,et al.  Mesenchymal Stem or Stromal Cells: Toward a Better Understanding of Their Biology? , 2010, Transfusion Medicine and Hemotherapy.

[41]  W. Marasco,et al.  Safety and complications reporting on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. , 2010, Current stem cell research & therapy.

[42]  Hélène Rouard,et al.  Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. , 2010, Blood.

[43]  M. Krampera,et al.  Mesenchymal stem cells for clinical application , 2010, Vox sanguinis.

[44]  Philippe Bierling,et al.  Osteoblastic differentiation of human mesenchymal stem cells with platelet lysate. , 2010, Biomaterials.

[45]  A. Cometa,et al.  Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors , 2009, Haematologica.

[46]  D. Strunk,et al.  Preparation of pooled human platelet lysate (pHPL) as an efficient supplement for animal serum-free human stem cell cultures. , 2009, Journal of visualized experiments : JoVE.

[47]  D. Gnatenko,et al.  The platelet proteome , 2009, Current opinion in hematology.

[48]  E. Andreu,et al.  Comparison of ex vivo expansion culture conditions of mesenchymal stem cells for human cell therapy , 2009, Transfusion.

[49]  D. Strunk,et al.  Human Alternatives to Fetal Bovine Serum for the Expansion of Mesenchymal Stromal Cells from Bone Marrow , 2009, Stem cells.

[50]  P. Delafontaine,et al.  Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. , 2009, Cell stem cell.

[51]  A. Kiani,et al.  Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium , 2009, Bone Marrow Transplantation.

[52]  I. Martin,et al.  Platelet lysate as a serum substitute for 2D static and 3D perfusion culture of stromal vascular fraction cells from human adipose tissue. , 2009, Tissue engineering. Part A.

[53]  Gerhard Nahler,et al.  Committee for Proprietary Medicinal Products (CPMP) , 2009 .

[54]  Regina Brunauer,et al.  Controversial issue: Is it safe to employ mesenchymal stem cells in cell-based therapies? , 2008, Experimental Gerontology.

[55]  E. Seifried,et al.  Homing of Mesenchymal Stem Cells , 2008, Transfusion Medicine and Hemotherapy.

[56]  T. Tonn,et al.  MSC – a Multipotent Stromal Cell in Search of Clinical Application , 2008, Transfusion Medicine and Hemotherapy.

[57]  N. Ilić,et al.  Points to Consider in Designing Mesenchymal Stem Cell-Based Clinical Trials , 2008, Transfusion Medicine and Hemotherapy.

[58]  I. Slaper-Cortenbach Current Regulations for the Production of Multipotent Mesenchymal Stromal Cells for Clinical Application , 2008, Transfusion Medicine and Hemotherapy.

[59]  H. Klingemann,et al.  Mesenchymal Stem Cells – Sources and Clinical Applications , 2008, Transfusion Medicine and Hemotherapy.

[60]  D. Strunk,et al.  Clinical Protocols for the Isolation and Expansion of Mesenchymal Stromal Cells , 2008, Transfusion Medicine and Hemotherapy.

[61]  Regina Brunauer,et al.  Changes of the Functional Capacity of Mesenchymal Stem Cells due to Aging or Age-Associated Disease – Implications for Clinical Applications and Donor Recruitment , 2008, Transfusion Medicine and Hemotherapy.

[62]  C. Choong,et al.  PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. , 2008, Blood.

[63]  H. Northoff,et al.  Characteristics of Mesenchymal Stem Cells – New Stars in Regenerative Medicine or Unrecognized Old Fellows in Autologous Regeneration? , 2008, Transfusion Medicine and Hemotherapy.

[64]  K. Bieback Basic Biology of Mesenchymal Stem Cells , 2008, Transfusion Medicine and Hemotherapy.

[65]  M. Rojewski,et al.  Phenotypic Characterization of Mesenchymal Stem Cells from Various Tissues , 2008, Transfusion Medicine and Hemotherapy.

[66]  A. Flake,et al.  In vivo Differentiation Potential of Mesenchymal Stem Cells: Prenatal and Postnatal Model Systems , 2008, Transfusion Medicine and Hemotherapy.

[67]  A. Ho,et al.  The Stromal Activity of Mesenchymal Stromal Cells , 2008, Transfusion Medicine and Hemotherapy.

[68]  Annalisa Pasini,et al.  Immune Modulation by Mesenchymal Stem Cells , 2008, Transfusion Medicine and Hemotherapy.

[69]  G. Dini,et al.  Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study , 2008, The Lancet.

[70]  P. Collas,et al.  Epigenetic Basis for the Differentiation Potential of Mesenchymal and Embryonic Stem Cells , 2008, Transfusion Medicine and Hemotherapy.

[71]  P. Genever,et al.  Transcriptional Control of Mesenchymal Stem Cell Differentiation , 2008, Transfusion Medicine and Hemotherapy.

[72]  P. Bourin,et al.  Mesenchymal Progenitor Cells: Tissue Origin, Isolation And Culture , 2008, Transfusion Medicine and Hemotherapy.

[73]  M. Ratajczak,et al.  Bone Marrow – Home of Versatile Stem Cells , 2008, Transfusion Medicine and Hemotherapy.

[74]  F. Guilak,et al.  In vitro Differentiation Potential of Mesenchymal Stem Cells , 2008, Transfusion Medicine and Hemotherapy.

[75]  L. Sensébé Clinical grade production of mesenchymal stem cells. , 2008, Bio-medical materials and engineering.

[76]  P. Collas,et al.  Genetic and epigenetic instability of human bone marrow mesenchymal stem cells expanded in autologous serum or fetal bovine serum. , 2008, The International journal of developmental biology.

[77]  Andrej-Nikolai Spiess,et al.  Accelerated and safe expansion of human mesenchymal stromal cells in animal serum‐free medium for transplantation and regenerative medicine , 2007, Journal of cellular physiology.

[78]  D. Maynard,et al.  Proteomic analysis of platelet α‐granules using mass spectrometry , 2007 .

[79]  D. Prockop,et al.  “Stemness” Does Not Explain the Repair of Many Tissues by Mesenchymal Stem/Multipotent Stromal Cells (MSCs) , 2007, Clinical pharmacology and therapeutics.

[80]  O. Ringdén,et al.  No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients , 2007, Haematologica.

[81]  S. E. Jacobsen,et al.  Potential risks of bone marrow cell transplantation into infarcted hearts. , 2007, Blood.

[82]  Karl Kashofer,et al.  Human platelet lysate can replace fetal bovine serum for clinical‐scale expansion of functional mesenchymal stromal cells , 2007, Transfusion.

[83]  P. Ljungman,et al.  Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells , 2007, Leukemia.

[84]  H. Klüter,et al.  Human AB Serum and Thrombin‐Activated Platelet‐Rich Plasma Are Suitable Alternatives to Fetal Calf Serum for the Expansion of Mesenchymal Stem Cells from Adipose Tissue , 2007, Stem cells.

[85]  A. Cometa,et al.  Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell‐therapy approaches: Further insights in the search for a fetal calf serum substitute , 2007, Journal of cellular physiology.

[86]  E. Lam,et al.  Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth , 2007, Leukemia.

[87]  J. Laine,et al.  N‐Glycolylneuraminic Acid Xenoantigen Contamination of Human Embryonic and Mesenchymal Stem Cells Is Substantially Reversible , 2007, Stem cells.

[88]  D. Sirbasku,et al.  Human platelet lysate contains growth factor activities for established cell lines derived from various tissues of several species , 1980, In Vitro.

[89]  J. White,et al.  Proteomic analysis of platelet alpha-granules using mass spectrometry. , 2007, Journal of thrombosis and haemostasis : JTH.

[90]  I. Rasmusson Immune modulation by mesenchymal stem cells. , 2006, Experimental cell research.

[91]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.

[92]  X. Holy,et al.  Platelet lysates promote mesenchymal stem cell expansion: A safety substitute for animal serum in cell‐based therapy applications , 2005, Journal of cellular physiology.

[93]  室井 一男 What's going on 造血器腫瘍 1)Human mesenchymal stem cells modulate allogeneic immune cell responses. Aggarwal S, Pittenger MF. Blood. 2005;105:1815-22. PMID:15494428. 2)Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Le Blanc K, Rasmusson I, Sun , 2005 .

[94]  F. Marini,et al.  Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. , 2005, Cytotherapy.

[95]  O. Kilian,et al.  Effects of platelet growth factors on human mesenchymal stem cells and human endothelial cells in vitro. , 2004, European journal of medical research.

[96]  Moustapha Hassan,et al.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells , 2004, The Lancet.

[97]  Shu-Ching Hsu,et al.  Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[98]  Antal Rot,et al.  Platelet-released supernatants increase migration and proliferation, and decrease osteogenic differentiation of bone marrow-derived mesenchymal progenitor cells under in vitro conditions , 2004, Platelets.

[99]  G. Sukhikh,et al.  Mesenchymal Stem Cells , 2002, Bulletin of Experimental Biology and Medicine.

[100]  J. Jonas,et al.  Subconjunctival injection of autologous platelet concentrate in the treatment of overfiltrating bleb. , 2003, Journal of glaucoma.

[101]  O. Ringdén,et al.  Mesenchymal Stem Cells Inhibit and Stimulate Mixed Lymphocyte Cultures and Mitogenic Responses Independently of the Major Histocompatibility Complex , 2003, Scandinavian journal of immunology.

[102]  Gerhard Gstraunthaler,et al.  Alternatives to the use of fetal bovine serum: serum-free cell culture. , 2003, ALTEX.

[103]  H. Klüter,et al.  Autologous concentrated platelet-rich plasma (cPRP) for local application in bone regeneration. , 2002, International journal of oral and maxillofacial surgery.

[104]  W. Koo,et al.  Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. , 2001, Blood.

[105]  F. Rendu,et al.  The platelet release reaction: granules' constituents, secretion and functions , 2001, Platelets.

[106]  S. Gerson,et al.  Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  M. Pittenger,et al.  Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.

[108]  Darwin J. Prockop,et al.  Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta , 1999, Nature Medicine.

[109]  A I Caplan,et al.  The mesengenic process. , 1994, Clinics in plastic surgery.

[110]  M. Lindberg,et al.  Adipose Tissue , 2018 .

[111]  M. Steiner,et al.  Platelets as a source of growth-promoting factor(s) for tumor cells. , 1980, Cancer research.

[112]  L. Sokoloff,et al.  Effect of platelet lysate on growth and sulfated glycosaminoglycan synthesis in articular chondrocyte cultures. , 1980, Arthritis and rheumatism.

[113]  N. Kulagina,et al.  Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. , 1974, Experimental Hematology.

[114]  A. Friedenstein,et al.  Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. , 1968, Transplantation.

[115]  Reflection paper on stem cell-based medicinal products , 2022 .